Fibrobody-Tracer Conjugate

Fibrobody-Tracer Conjugates are novel diagnostic agents developed to enable the non-invasive detection and monitoring of active fibrosis *in vivo*. These conjugates consist of a "Fibrobody"—a variable fragment of a heavy chain-only antibody (VHH) engineered for high specificity—linked to a PET tracer (such as 89Zr). The resulting molecule selectively binds to activated myofibroblasts by targeting platelet-derived growth factor receptor beta (PDGFRβ), which is overexpressed on these cells during fibrogenesis. Upon administration, the conjugate accumulates in fibrotic tissues and can be visualized using PET imaging, allowing clinicians to identify areas of active fibrosis and monitor disease progression or response to therapy. The technology is being developed primarily for applications such as liver fibrosis but may have broader utility across other fibrotic diseases[1][3][4][6].

Brand names

Fibrobody

Other names

Fibrobody®-Tracer ConjugateFTCFibrobody®-Tracer Conjugates